Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Clinical Trial to Evaluate Efficacy and Safety of Twice-daily Applications of Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema (DELTA TEEN)

Next Previous
Trial Profile

A Phase 3 Clinical Trial to Evaluate Efficacy and Safety of Twice-daily Applications of Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema (DELTA TEEN)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Delgocitinib (Primary)
  • Indications Eczema
  • Focus Registrational; Therapeutic Use
  • Acronyms DELTA-TEEN
  • Sponsors LEO Pharma

Most Recent Events

  • 15 Dec 2025 According to a Leo Pharma media release, based on data from this trial, the company has submitted a label expansion application to EMA to expand Anzupgo (delgocitinib) cream to adolescent patients (12-1 years) with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate.The label expansion application has been accepted for review by EMA.
  • 21 Oct 2025 According to a Leo Pharma media release, data from this trial will be presented at the upcoming 2025 Fall Clinical Dermatology Conference
  • 18 Sep 2025 According to a LEO Pharma A/S media release, data from this trial presented at the 34th European Academy of Dermatology and Venereology (EADV).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top